Alpha Cognition, Inc. has three programs in its therapeutic pipeline: Alzheimer’s disease, Traumatic Brain Injury, and ALS. ALPHA-1062 enteric-coated tablet has completed two human clinical programs and is entering the final pivotal trial stages. A regulatory pathway has been reviewed and commented on by the US FDA and we are progressing on that path. Meetings with Japanese authorities occurred in the early part of 2020 and an approval pathway for Japan was defined. Meetings with European authorities were also held, and the agency has provided advice for the approval path for ALPHA-1062.